Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| QTTB | 8-K | bullish | 7/10 | Q32 Bio announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial for bempikibart in severe | Jul 13, 2026 |
| VYGR | 8-K | bullish | 6/10 | Voyager Therapeutics presented favorable GLP toxicology data for VY1706, its tau-silencing gene therapy for Alzheimer's | Jul 13, 2026 |
| DARE | 8-K | neutral | 2/10 | Dare Bioscience filed an 8-K to furnish a corporate investor presentation dated July 13, 2026, as Exhibit 99.1. The docu | Jul 13, 2026 |
| ONCY | 8-K | neutral | 4/10 | Oncolytics Biotech provided a clinical and regulatory update on its REO 033 study in RAS-mutant MSS colorectal cancer, r | Jul 13, 2026 |
| SLXN | DEFA14A | neutral | 3/10 | Silexion Therapeutics adjourned its extraordinary general meeting to July 20, 2026, without conducting business. The mee | Jul 13, 2026 |
| ESPR | 25-NSE | bullish | 7/10 | Esperion Therapeutics has been delisted from Nasdaq following its acquisition by ArchiMed (via Essence Parent Inc.) for | Jul 13, 2026 |
| NVO | 6-K | neutral | 2/10 | Novo Nordisk filed a routine 6-K providing a weekly update on its ongoing DKK 15 billion share repurchase program. There | Jul 13, 2026 |
| ESPR | 8-K | bullish | 7/10 | Esperion Therapeutics completed its acquisition by ArchiMed (via Essence Parent Inc.) on July 13, 2026, for $3.16 per sh | Jul 13, 2026 |
| ARTL | PRESS-RELEASE | neutral | 4/10 | Artelo Biosciences announced nonclinical results showing ART27.13 reduced neuropathic pain behaviors in a paclitaxel-ind | Jul 13, 2026 |
| EWTX | 8-K | bullish | 7/10 | Edgewise Therapeutics completed the sale of its sevasemten muscular dystrophy program to Servier for $1.55 billion in up | Jul 13, 2026 |
| MTNB | 8-K | bearish | 7/10 | Matinas BioPharma entered into a definitive business combination agreement with GH Power, a clean-energy company, in a r | Jul 13, 2026 |
| ANRO | 8-K | bullish | 6/10 | Alto Neuroscience disclosed a preliminary cash balance of ~$244.2M as of June 30, 2026 (down from $264.2M at Q1 end) and | Jul 13, 2026 |
| ANIP | PRESS-RELEASE | bullish | 6/10 | ANI Pharmaceuticals reported positive topline Phase 4 data for ILUVIEN in chronic non-infectious uveitis affecting the p | Jul 13, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's Laboratories filed a Form 6-K to announce the date of its Q1 FY27 earnings release and earnings call on July | Jul 13, 2026 |
| GSK | 6-K | bullish | 6/10 | GSK announced positive interim results from the registrational phase II AZUR-1 trial of Jemperli (dostarlimab) in dMMR/M | Jul 13, 2026 |
| AGEN | 8-K | bearish | 6/10 | Agenus entered into a securities purchase agreement for a ~$85M PIPE financing led by Commodore Capital, issuing shares | Jul 13, 2026 |
| BIIB | ANALYST-UPGRADE | bullish | 3/10 | Truist Securities double-upgraded Biogen (BIIB) from Hold to Buy on July 13, raising the price target to $235 from $190, | Jul 13, 2026 |
| AMPH | 8-K | neutral | 2/10 | Amphastar Pharmaceuticals appointed Anthony Pierce as a new independent Class III director, expanding the board from 10 | Jul 13, 2026 |
| AVCRF | 6-K | neutral | 2/10 | Analysis based on filing metadata only, document content was unavailable. Avricore Health Inc. filed a Form 6-K with the | Jul 13, 2026 |
| CBIO | EFFECT | neutral | 3/10 | Analysis based on filing metadata only, document content was unavailable. Crescent BioPharma's registration statement ha | Jul 13, 2026 |
| ONMD | EFFECT | neutral | 3/10 | Analysis based on filing metadata only, document content was unavailable. OneMedNet Corp (ONMD) filed an EFFECT notice i | Jul 13, 2026 |
| INO | EFFECT | bearish | 6/10 | Inovio Pharmaceuticals' universal shelf registration (S-3) filed July 2, 2026 has become effective, allowing the company | Jul 13, 2026 |
| CRVO | EFFECT | bearish | 4/10 | CervoMed Inc.'s shelf registration (S-3) has become effective via an EFFECT notice, enabling selling stockholders to res | Jul 13, 2026 |
| EVAX | 6-K | neutral | 3/10 | Evaxion announced new preclinical data for its CMV vaccine program EVX-V1, presented at an industry conference. The data | Jul 13, 2026 |
| ALMR | PRESS-RELEASE | neutral | 4/10 | Alamar Biosciences announced a partnership with leading research universities to profile ~21,000 plasma samples from 10, | Jul 13, 2026 |
| EVAX | PRESS-RELEASE | neutral | 3/10 | Evaxion presented new preclinical data at the International Herpesvirus Workshop 2026 for its CMV vaccine program EVX-V1 | Jul 12, 2026 |
| NVO | COURT-RULING | neutral | 2/10 | The court granted a fourth joint stipulation to stay discovery in Novo Nordisk's case against Aesthetic Center of Plasti | Jul 11, 2026 |
| APGE | CLUSTER | neutral | 2/10 | CEO Michael Thomas Henderson sold $2.67M and CMO Carl Dambkowski sold $730K of APGE shares in a small cluster. Combined | Jul 10, 2026 |
| EVMN | CLUSTER | neutral | 3/10 | Two Evommune insiders (Director Arthur S. Kirsch and CFO Kyle Carver) made open-market stock purchases totaling $146K ov | Jul 10, 2026 |
| PALI | CLUSTER | neutral | 2/10 | A small insider cluster at Palisade Bio (PALI) shows mixed activity: Director Baltera purchased ~$191K worth of shares o | Jul 10, 2026 |